Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study has been terminated.
( funding )
Study NCT00636155 Information provided by Duke University
First Received on January 22, 2008. Last Updated on November 26, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma, Small Lymphocytic
Leukemia, Lymphocytic, Chronic
Additional conditions recognized in this trial
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Lymphoma
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
cenersen sodium
Rituximab
Cyclophosphamide
Fludarabine
Additional drug interventions recognized in this trial
Fludarabine monophosphate
More general drug interventions related to this trial
Alkylating Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
David Rizzieri
Eleos, Inc.
Back to top of Main Content
